Liver Disease Models and Efficacy Services

The liver is an essential hub for material and energy metabolic processes. The impact of alcohol, drugs, and toxic chemicals usually produces acute or chronic liver injury, which can progress to liver fibrosis, cirrhosis, or liver cancer if not appropriately managed. Consequently, experimental animal models of liver disease are essential for investigating the pathophysiology of liver disease and screening therapeutic medicines.GemPharmatech offers liver fibrosis models, metabolic dysfunction-associated steatohepatitis models, and related-efficacy evaluation services.

Liver Fibrosis Models

Liver fibrosis refers to a pathological process marked by the excessive deposition of extracellular matrix in the liver and serves as an intermediate in the progression of several liver disorders. Selecting appropriate animal models of liver fibrosis is imperative to understanding the etiology of liver fibrosis as well as selecting the most efficient screening method for anti-liver fibrosis medicines. GemPharmatech established drug-induced liver fibrosis models, which can be utilized to examine the therapeutic effects of medications on liver fibrosis.
- CCl4-induced liver fibrosis model

Metabolic Dysfunction-associated Steatohepatitis (MASH) Models

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a disorder in which a substantial quantity of fat accumulates in the liver of non-alcoholic individuals. Metabolic dysfunction-associated steatohepatitis (MASH) is a severe form of MASLD characterized by fatty liver lesions, inflammation, vacuolation, and fibrosis in the liver lobules. Preclinical animal models are crucial to develop novel anti-MASH medications, and GemPharmatech has created several dietary or mutation-induced MASH mice models for preclinical efficacy testing.
- HFD+CCl4-induced MASH models
- HFD-induced BKS-db MASH models
- HFD-induced C57BL/60Alms 1-del MASH models
- Other MASH models
- Liver disease-related target humanized mouse models

Test items

- Body weight, food intake；
- Fibrosis scoring, fibrosis marker assessment (TGFβ1& COL1A1& TIMP1& ACTA2 etc.)
- Blood glucose and lipid, HbA1c, GTT; histological analysis (H&E staining, Sirius red staining).

CCl4-induced Liver Fibrosis ModelsHFD+CCl4-induced MASH ModelsBKS-db MASH ModelsB6-Alms1-del MASH ModelsOther MASH Models

TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。